MediciNova Positive Phase IIa Clinical Study Results for MN-221, a Novel Treatment for Status Asthmaticus

Oct 9, 2007 - MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), announced positive results from a Phase IIa clinical study of MN-221, its novel intravenous product candidate for the treatment of status asthmaticus* (acute severe asthma attack)... MediciNova's Press Release -